• Infertility

Menopur Generic Name & Formulations

General Description

Menotropins (follicle-stimulating hormone 75 IU + luteinizing hormone 75 IU); per vial; lyophilized pwd for SC inj after reconstitution.

How Supplied

Vials—5 (w. diluent)

Menopur Indications


Stimulation of multiple follicles in ovulatory patients undergoing Assisted Reproductive Technologies (ART) who have previously received pituitary suppression.

Menopur Dosage and Administration


Individualize. Use lowest effective dose. Initially 225 IU SC inj daily for 5 days starting on Day 2 or 3 of cycle; or, may be given in combination with Bravelle (total initial dose: max 225 IU [Menopur 150 IU + Bravelle 75 IU; or Menopur 75 IU + Bravelle 150 IU]). Adjust dose based on response in increments of up to 150 IU at intervals of at least 2 days; max 450 IU daily; usual max 20 days. Induce final maturation/ovulation of follicles with hCG (see Precautions).


Not applicable.

Menopur Contraindications


Primary ovarian failure. Uncontrolled non-gonadal endocrinopathies (eg, thyroid, adrenal, pituitary). Undiagnosed abnormal uterine bleeding. Ovarian cysts or enlargement. Tumor of pituitary, hypothalamus, breast, ovary, or uterus. Pregnancy (Cat.X).

Menopur Boxed Warnings

Not Applicable

Menopur Warnings/Precautions


Do complete gynecological and endocrinological exam first. Risk of ovarian hyperstimulation syndrome (OHSS); monitor for at least 2 weeks after hCG administration. Discontinue if severe OHSS occurs; consider hospitalization (see full labeling). Abnormal ovarian enlargement; monitor ovarian response and/or measure serum estradiol levels. Do not give hCG if abnormally enlarged ovaries on last day of Menopur therapy to reduce OHSS development. Increased risk of thromboembolic events in severe obesity, thrombophilia, pregnancy, personal or family history of thrombosis. Nursing mothers: not recommended.

Menopur Pharmacokinetics

See Literature

Menopur Interactions

Not Applicable

Menopur Adverse Reactions

Adverse Reactions

Abdominal cramps/pain, abdomen enlarged, headache, nausea, inj site reactions; ovarian enlargement or cysts, OHSS, thromboembolic events, ovarian torsion, multi-fetal gestation and birth, ectopic pregnancy, spontaneous abortion, ovarian neoplasms, risk of congenital malformations, hypersensitivity reactions.

Menopur Clinical Trials

See Literature

Menopur Note

Not Applicable

Menopur Patient Counseling

See Literature